Hemogenyx 报告其实验性治疗的积极试验结果，并向主要员工提供股份。 Hemogenyx reports positive trial results for its experimental treatment and grants shares to key staff.

血激素制药公司报告说,在进行临床试验以进行可能的治疗方面有所进展,最新结果显示,有积极的安全和功效信号。 Hemogenyx Pharmaceuticals reports progress in its clinical trial for a potential treatment, with updated results indicating positive safety and efficacy signals. 该公司还宣布向关键人员颁发股份奖,作为其目前支持研究与发展努力的一部分。 The company also announced the granting of share awards to key personnel as part of its ongoing efforts to support research and development.